IL271884B2 - Compounds to reduce lipotoxic damage - Google Patents
Compounds to reduce lipotoxic damageInfo
- Publication number
- IL271884B2 IL271884B2 IL271884A IL27188420A IL271884B2 IL 271884 B2 IL271884 B2 IL 271884B2 IL 271884 A IL271884 A IL 271884A IL 27188420 A IL27188420 A IL 27188420A IL 271884 B2 IL271884 B2 IL 271884B2
- Authority
- IL
- Israel
- Prior art keywords
- compound
- pharmaceutically acceptable
- subject
- acceptable salt
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
- C07D305/12—Beta-lactones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762531454P | 2017-07-12 | 2017-07-12 | |
| PCT/US2018/041796 WO2019014434A1 (en) | 2017-07-12 | 2018-07-12 | COMPOUNDS FOR REDUCING LIPOTOXIC LESIONS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL271884A IL271884A (en) | 2020-02-27 |
| IL271884B1 IL271884B1 (en) | 2023-03-01 |
| IL271884B2 true IL271884B2 (en) | 2023-07-01 |
Family
ID=65002124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL271884A IL271884B2 (en) | 2017-07-12 | 2020-01-07 | Compounds to reduce lipotoxic damage |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US11339126B2 (enExample) |
| EP (2) | EP3651784B1 (enExample) |
| JP (1) | JP7224331B2 (enExample) |
| KR (1) | KR102679975B1 (enExample) |
| CN (1) | CN111343999B (enExample) |
| AU (2) | AU2018300985B2 (enExample) |
| BR (1) | BR112020000635B1 (enExample) |
| CA (1) | CA3069526A1 (enExample) |
| DK (1) | DK4218753T3 (enExample) |
| ES (2) | ES2934883T3 (enExample) |
| IL (1) | IL271884B2 (enExample) |
| PL (2) | PL4218753T3 (enExample) |
| SG (1) | SG11202000239XA (enExample) |
| WO (1) | WO2019014434A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3651784B1 (en) | 2017-07-12 | 2022-09-28 | Mayo Foundation for Medical Education and Research | Compounds for the reducing lipotoxic damage |
| AU2022261098A1 (en) * | 2021-04-23 | 2023-10-26 | Panafina, Inc. | Methods of synthesizing lipstatin derivatives |
| CN114560887B (zh) * | 2022-02-15 | 2024-01-26 | 安徽美致诚药业有限公司 | 一种制备奥利司他的中间体的制备方法 |
| CA3246171A1 (en) * | 2022-03-31 | 2023-10-05 | Mayo Foundation For Medical Education And Research | METHODS AND MATERIALS FOR THE TREATMENT OF PANCREATIC DISEASES AND DISORDERS |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA859575B (en) * | 1984-12-21 | 1986-08-27 | Hoffmann La Roche | Oxetanones |
| CA1270837A (en) * | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| IL97148A (en) * | 1990-02-26 | 1996-11-14 | Hoffmann La Roche | Oxetanones a process for their manufacture and pharmaceutical compositions containing them |
| FR2754827B1 (fr) | 1996-10-17 | 1998-12-24 | Biocem | Lipases pancreatiques et/ou colipases recombinantes et polypeptides dervies produits par les plantes, leurs procedes d'obtention et leurs utilisations |
| FR2758143B1 (fr) | 1997-01-07 | 1999-02-19 | Laphal Laboratoire De Pharmaco | Inhibiteurs specifiques de la lipase pancreatique et leurs applications |
| US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
| US20040018197A1 (en) | 2002-04-26 | 2004-01-29 | Promega Corporation | Treatment for weight loss |
| DE102004009076A1 (de) | 2004-02-23 | 2005-10-27 | Solvay Pharmaceuticals Gmbh | Alkylcarbamat-substituierte β-Lactone, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| EP1803714A1 (en) | 2005-12-27 | 2007-07-04 | KRKA, tovarna zdravil, d.d., Novo mesto | Process for preparing crystalline forms of orlistat |
| US8258321B2 (en) * | 2007-10-31 | 2012-09-04 | Burnham Institute For Medical Research | Beta-lactone compounds |
| US9023887B2 (en) | 2011-04-15 | 2015-05-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | Lipase inhibitors for the treatment of pancreatitis and organ failure |
| US20150099800A1 (en) * | 2012-05-24 | 2015-04-09 | Northeastern University | Novel lipase inhibitors, reporter substrates and uses thereof |
| CN106470804B (zh) | 2014-06-30 | 2019-09-10 | 工机控股株式会社 | 电动工具 |
| EA034983B1 (ru) | 2014-12-22 | 2020-04-14 | Университет Либре Де Брюссель | Композиция, содержащая ванкомицин и орлистат |
| WO2017079299A1 (en) | 2015-11-03 | 2017-05-11 | Mayo Foundation For Medical Education And Research | Using colipase inhibitors to treat pancreatitis |
| EP3651784B1 (en) | 2017-07-12 | 2022-09-28 | Mayo Foundation for Medical Education and Research | Compounds for the reducing lipotoxic damage |
-
2018
- 2018-07-12 EP EP18831486.8A patent/EP3651784B1/en active Active
- 2018-07-12 KR KR1020207003413A patent/KR102679975B1/ko active Active
- 2018-07-12 PL PL22197886.9T patent/PL4218753T3/pl unknown
- 2018-07-12 EP EP22197886.9A patent/EP4218753B1/en active Active
- 2018-07-12 DK DK22197886.9T patent/DK4218753T3/da active
- 2018-07-12 PL PL18831486.8T patent/PL3651784T3/pl unknown
- 2018-07-12 JP JP2020501125A patent/JP7224331B2/ja active Active
- 2018-07-12 AU AU2018300985A patent/AU2018300985B2/en active Active
- 2018-07-12 BR BR112020000635-1A patent/BR112020000635B1/pt active IP Right Grant
- 2018-07-12 US US16/629,842 patent/US11339126B2/en active Active
- 2018-07-12 ES ES18831486T patent/ES2934883T3/es active Active
- 2018-07-12 CA CA3069526A patent/CA3069526A1/en active Pending
- 2018-07-12 WO PCT/US2018/041796 patent/WO2019014434A1/en not_active Ceased
- 2018-07-12 ES ES22197886T patent/ES3064684T3/es active Active
- 2018-07-12 SG SG11202000239XA patent/SG11202000239XA/en unknown
- 2018-07-12 CN CN201880057761.7A patent/CN111343999B/zh active Active
-
2020
- 2020-01-07 IL IL271884A patent/IL271884B2/en unknown
-
2022
- 2022-04-20 US US17/725,281 patent/US11623915B2/en active Active
-
2023
- 2023-03-03 US US18/178,062 patent/US11976040B2/en active Active
-
2024
- 2024-04-17 US US18/637,793 patent/US12325690B2/en active Active
- 2024-12-11 AU AU2024278291A patent/AU2024278291A1/en active Pending
-
2025
- 2025-05-14 US US19/207,836 patent/US20250340512A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12325690B2 (en) | Compounds for the reducing lipotoxic damage | |
| USRE38103E1 (en) | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 | |
| JP6989505B2 (ja) | Ｍａｌｔ１阻害剤およびその使用 | |
| BR112018004863B1 (pt) | Compostos usados para a prevenção ou aplicação terapêutica de hiperuricemia ou gota | |
| US20210040115A1 (en) | Fused ring heteroaryl compounds as ripk1 inhibitors | |
| JP2009539838A (ja) | マクロファージ転位阻害因子阻害剤としてのオキシム誘導体 | |
| HK40029799B (en) | Compounds for the reducing lipotoxic damage | |
| HK40029799A (en) | Compounds for the reducing lipotoxic damage | |
| WO2023272571A1 (zh) | 2,3-环氧丁二酰衍生物的医药用途 | |
| RU2776343C2 (ru) | Соединения для снижения липотоксического повреждения | |
| WO2024020409A1 (en) | Therapeutic compounds, formulations, and use thereof | |
| US20140142189A1 (en) | Methionine analogs and methods of using same | |
| US8680125B2 (en) | Fullerene therapies for inflammation | |
| CN115697349A (zh) | 用于治疗细菌感染的烟酰胺单核苷酸衍生物 | |
| JPWO1996006825A1 (ja) | グアニジノメチルシクロヘキサンカルボン酸エステル誘導体 | |
| US20230116468A1 (en) | Method of treating bacterial infections and pharmaceutical composition for treating bacterial infections |